4967 — Kobayashi Pharmaceutical Co Income Statement
0.000.00%
- ¥389bn
- ¥331bn
- ¥166bn
- 82
- 31
- 22
- 40
Annual income statement for Kobayashi Pharmaceutical Co, fiscal year end - December 31st, JPY millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | Yuho | Yuho | Yuho | Yuho | Yuho |
| Standards: | JAS | JAS | JAS | JAS | JAS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 150,514 | 155,252 | 166,258 | 173,455 | 165,600 |
| Cost of Revenue | |||||
| Gross Profit | 85,266 | 88,774 | 92,331 | 96,376 | 87,603 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 125,859 | 129,646 | 139,912 | 147,823 | 154,271 |
| Operating Profit | 24,655 | 25,606 | 26,346 | 25,632 | 11,329 |
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | 26,635 | 27,636 | 27,950 | 27,559 | 13,914 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 19,205 | 19,716 | 20,023 | 20,338 | 10,072 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | 19,205 | 19,716 | 20,023 | 20,338 | 10,068 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | 19,205 | 19,715 | 20,022 | 20,338 | 10,067 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 262 | 267 | 276 | 285 | 287 |
| Dividends per Share |